Three years ago, synthetic cathinones were a footnote in European drug reporting. By 2024 they were the story. EU seizures went from 4.5 tonnes in 2021 to 37 tonnes in 2023, over eight times in two years, then climbed to 48.5 tonnes in 2024, with preliminary data suggesting the first half of 2025 kept pace. For scale: cathinone seizures in 2023 came to more than three times the amphetamine seized across the EU that year. A market that size is not finding its feet. It is replacing what came before it.

Synthetic cathinones are lab-made stimulants, chemically related to cathinone, the active compound in the khat plant. The family is large, and that breadth is part of the point: when regulators ban one compound, chemists adjust the molecule and the product reappears under a new name. During the 2014 and 2015 legal highs era, close to 30 new cathinones surfaced each year. By 2024 that had dropped to around seven, which looks like progress until you set it against the tonnage, which kept climbing. Fewer new compounds, more product: the market consolidated rather than shrank.

Price and availability drove the rise. The EUDA’s European Drug Report describes synthetic cathinones as affordable alternatives to amphetamine and cocaine in parts of Europe, frequently sold as supposedly legal substitutes for both. The supply chain is efficient. Bulk precursor chemicals arrive mainly from India, entering the EU predominantly through the Netherlands, and manufacturing has concentrated in Poland. Police dismantled 29 synthetic cathinone production sites across the EU in 2022, 53 in 2023, and 63 in 2024, most of them Polish. Among the 2024 raids, the Central Bureau of Police Investigation seized 800 kilograms in a single operation at a laboratory in Lublin.

Poland became the continent’s primary production hub for concrete reasons: geography, existing chemical manufacturing capacity, and accessible precursor routes into Central Europe. The EUDA and Polish law enforcement co-hosted an expert workshop in Warsaw in 2025, drawing forensic and policing specialists from across the EU and neighbouring states, treating this as a regional problem with a Polish centre of gravity.

The risk that most directly concerns anyone buying stimulants in Europe right now is not on a production floor in Lublin. It is in the product. Drug checking services and the EU Early Warning System have confirmed synthetic cathinones turning up in MDMA, as adulterants or outright substitutes. Separately, through 2025, the cathinone NEP was increasingly sold as a different cathinone, 3-MMC, causing unintended consumption and a rise in poisonings. EUDA drug-checking data adds a parallel swap: samples sold as 3-MMC often contained 2-MMC instead. These are not equivalent substances. If you do not know what you have taken, you cannot make a sensible judgment about what it will do to you.

The EU’s response entered into force on 12 January 2026, when three cathinones, 2-MMC, 4-BMC and NEP, were brought under legal control by Delegated Directive (EU) 2025/2062. Member states have until 12 July 2026 to pass the corresponding national legislation. In July 2025 the Netherlands went further, introducing generic controls covering synthetic cathinones as a class, which the EUDA’s 2026 report suggests may significantly affect importation. Real steps, but they are chasing a market that moved 48.5 tonnes last year and has shown no sign of pausing to wait.

What the harms actually look like

The danger isn’t abstract. Synthetic cathinones show up in acute drug-toxicity presentations at hospitals across the Euro-DEN Plus network, and they kill: seven countries with data reported 27 deaths involving synthetic cathinones in 2022, up from 18 the year before, concentrated in Finland, Estonia and Portugal. Those are the deaths that get counted, in the minority of countries that test for cathinones specifically, so the real figure is higher than the record shows.

The pattern behind the harm is mis-selling. The EUDA’s central warning about this market is that people often do not know what they have bought. Products sold as MDMA turn out to contain cathinones. Something sold as 3-MMC turns out to be 2-MMC, or NEP. Each swap moves the user onto a substance with a different potency and a different dose-response curve, without them knowing to adjust. NEP and alpha-PHiP (sold as “Flakka”) are flagged by the EUDA as capable of causing localised health problems precisely because they slip past detection until people are already being harmed.

Polydrug use raises the stakes again. Cathinones now appear in syringe residue alongside amphetamines, cocaine, opioids and other substances, often in combination, which increases overdose risk and makes acute poisoning harder to treat. A stimulant taken with a depressant, or three unknown substances taken together, is a harder emergency to manage than any one of them alone.

For anyone using regardless, the single fact that matters is the one running through all of this: you cannot dose, predict or stay within a safe margin on a substance you cannot identify. Drug-checking services, where they operate, are the only way to find out what a sample actually contains before it goes in a body. The EUDA runs its work through those services and the Early Warning System for a reason. They are the part of the response aimed at the person holding the bag, not the supply chain.